RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, today presented five posters at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The data presented included results from studies focused on identifying compounds from PolyMedix’s library of novel defensin mimetic antibiotics to address foodborne infections and biowarfare pathogens. In addition, results were presented showing antimicrobial activity in human serum collected from subjects in PolyMedix’s Phase 1B clinical trial with its lead defensin mimetic, PMX-30063.
